Skip to main navigation

Skip to content

Side Menu

About
Our Programs
Our Platform
Scientific Presentations
Publications
Inside Seres
Open Positions
Investors and News
Contact Us
Contact Medical Affairs

Press Releases

Seres' news, events and other information can be found throughout the pages below.

Investor Relations

Stock Information
News and Events
- Press Releases
- Events & Presentations
Financial Information
- SEC Filings
- Annual Reports
Corporate Governance
Shareholder Services

Press Releases

Keyword Search

Year

May 12, 2026

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

May 05, 2026

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 04, 2026

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

Apr 20, 2026

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Apr 20, 2026

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Apr 09, 2026

Seres Therapeutics to Present at CARB-X Investor Day

Mar 12, 2026

Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 02, 2026

Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

Feb 12, 2026

Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

Jan 06, 2026

Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy

Shareholder Tools

RSS Feeds
E-mail Alerts
Print

© 2026 Seres Therapeutics.

Footer Left Menu

Privacy Policy
Terms of Use

Follow us on Linkedin
Follow us on Twitter
Follow us on Facebook